[1] 周文.药物流行病学[M].1版.北京:人民卫生出版社,2007:7-8. [2] 詹思延.药物流行病学研究新方法概述-药物流行病学研究新方法系列讲座(一)[J].中国药物应用与监测,2009;6(1):59-62. [3] 闫永平,陈薇.临床流行病学[M].1版.北京:人民卫生出版社,2009:245. [4] Lago R M, Singh P P, Nesto R W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials[J]. Lancet, 2007, 370(9593): 1129-1136. [5] Singh S, Loke Y K, Furberg C D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis[J]. JAMA, 2007, 298(10): 1189-1195. [6] Nissen S E, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes[J]. N Engl J Med, 2007;356(24): 2457-2471. [7] 中华医学会糖尿病学分会,中华医学会内分泌学分会.中华糖尿病学分会内分泌学分会:关于文迪雅心脏安全性的联合共识[EB/OL]. 2008-5-17 [2009-12-28]. http://www. diab. net.cn / news_show.jsp?id=24.html. [8] Home P D, Pocock S J, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial [J]. Lancet, 2009, 373(9681):2125-2135. [9] Loke Y K, Singh S, Furberg C D. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis[J]. CMAJ, 2009, 180(1): 32-39. [10] Lazarou J, Pomeranz B H, Corey P N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies[J]. JAMA, 1998, 279(15): 1200-1205. [11] McDowell S E, Coleman J J, Ferner R E. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine[J]. BMJ, 2006, 332(7551):1177-1181. [12] Hernandez A V, Walker E, Ioannidis J P, et al. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone[J]. Am Heart J, 2008, 156(1):23-30. [13] Rucker G, Schumacher M. Simpson's paradox visualized: the example of the rosiglitazone meta-analysis[J]. BMC Med Res Meth- odol, 2008,8:34. [14] Shuster J J, Jones L S, Salmon D A. Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death [J]. Stat Med, 2007, 26(24):4375-4385. [15] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement[J]. J Clin Epidemiol, 2009,62(10):1006-1012. [16] Papanikolaou P N, Ioannidis J P. Availability of large-scale evidence on specific harms from systematic reviews of randomized trials[J]. Am J Med, 2004, 117(8):582-589. [17] Ioannidis J P, Evans S J, Gotzsche P C, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement [J]. Ann Intern Med, 2004, 141(10):781-788. |